

**Emergency Use Authorization (EUA) for Sotrovimab 500 mg  
Center for Drug Evaluation and Research (CDER) Memorandum on Fact Sheet  
Update**

**Identifying Information**

Application Type (EUA or Pre-EUA) If EUA, designate whether pre-event or intra-event EUA request.	EUA
EUA Application Number(s)	EUA 000100
Sponsor (entity requesting EUA or pre-EUA consideration), point of contact, address, phone number, fax number, email address	<p><u>EUA Sponsor</u> GlaxoSmithKline Research &amp; Development Limited 980 Great West Road Brentford Middlesex, TW8 9GS UK</p> <p><u>GSK US Point of Contact</u> Debra H. Lake, M.S. Sr. Director Global Regulatory Affairs GlaxoSmithKline 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709-3398 Email: (b) (6) Phone: (b) (6)</p>
Manufacturer	GlaxoSmithKline, Parma.
Submission Date	June 22, 2021
Receipt Date	June 22, 2021
Review Completion Date	June 24, 2021
OND Division / Office	Division of Antivirals (DAV) / Office of Infectious Diseases (OID)
Proprietary Name	None
Established Name/Other names used during development	Sotrovimab (VIR-7831)
Dosage Forms/Strengths	Sterile solution for injection, 500mg/8 mL vial
Therapeutic Class	SARS-CoV-2 spike protein directed human IgG1k monoclonal antibody (mAb)

Intended Population	Treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death
---------------------	--

**I. Summary of Fact Sheet Revision**

In the Fact Sheet for Healthcare Providers the Sponsor proposes to remove the requirement to prime the infusion set with a separate 0.9% sodium chloride injection. The rationale for this change is to simplify the administration process and maintain consistency with standard clinical practice.

**II. Recommendations**

The proposed revision to the Fact Sheet for Healthcare Providers is acceptable and does not alter the benefit-risk analysis or conclusion in the initial review to support authorization of EUA 100.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

SARITA D BOYD  
07/08/2021 10:55:31 AM

KIMBERLY A STRUBLE  
07/09/2021 11:05:46 AM